Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780775 | 0.81 | TAAR1 (0.46) | SLC1A3SLC1A2SLC1A1TAAR1MEN1 | |
| SCHEMBL8360058 | 0.78 | ALDH1A1 (0.48) | TAAR1MEN1KDM4AALDH1A1MAPT | |
| SCHEMBL4952656 | 0.77 | CA2 (0.58) | ALDH1A1KMT2ACA2CA9HPGD | |
| SCHEMBL9052675 | 0.76 | PRMT6 (0.55) | DRD2DRD3 | |
| SCHEMBL8707908 | 0.76 | NR3C1 (0.32) | PARP15PARP10PARP3 | |
| SCHEMBL5424489 | 0.74 | MEN1 (0.44) | SLC1A3SLC1A2SLC1A1TAAR1MEN1 | |
| SCHEMBL5302748 | 0.73 | TAAR1 (0.41) | SLC1A3SLC1A2SLC1A1TAAR1MEN1 | |
| SCHEMBL1145683 | 0.73 | — | — | |
| SCHEMBL22260950 | 0.72 | MME (0.42) | SLC1A3SLC1A2SLC1A1TAAR1MEN1 | |
| SCHEMBL22260951 | 0.72 | MME (0.42) | SLC1A3SLC1A2SLC1A1TAAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144732-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| EP-3152206-A1 | ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015188051-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015188051-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| US-8158663-B2 | N-[2-thiazolylidene- or 2-oxazolylidene]carbo- or heterocyclecarboxyamides, e.g., 5-chloro-2-methoxy-N-[(2Z)-3-(2-methoxyethyl)-5,5-dimethyl-1,3-thiazolidin-2-ylidene]benzamide; treating neuropathic, nociceptive, and inflammatory pain and immune, respiratory, and cardiovascular disorders | ABBOTT LABORATORIES (US) | 2012-04-17 | — | — | US | disclosed |
| WO-2008079687-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153883-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | ENPP2, ATXN10, ATXN2 | SLC1A3 560/4885SLC1A2 434/4885SLC1A1 621/4885 |
| US-10144732-B2 | ATX modulating agents | ENPP2, ATXN10, ATXN2 | SLC1A3 559/4885SLC1A2 433/4885SLC1A1 620/4885 |
| US-20080153883-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | SLC1A3 2994/4885SLC1A2 1942/4885SLC1A1 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.